Previous close | 135.68 |
Open | 138.10 |
Bid | 138.74 x 0 |
Ask | 138.92 x 0 |
Day's range | 137.92 - 138.10 |
52-week range | 133.12 - 158.80 |
Volume | |
Avg. volume | 22 |
Market cap | 334.391B |
Beta (5Y monthly) | 0.53 |
PE ratio (TTM) | 21.93 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 4.55 (3.30%) |
Ex-dividend date | 20 May 2024 |
1y target est | N/A |
NEW BRUNSWICK, N.J., June 21, 2024--Johnson & Johnson (NYSE: JNJ) announced today that it has successfully completed the acquisition of Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850 million in cash with potential for an additional milestone payment, as announced on May 16, 2024.
Johnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active Crohn's disease. This marks the second submission to the FDA for TREMFYA® in inflammatory bowel disease this year following an application in March for moderately to severely active ulcerative colitis.a
Johnson & Johnson (NYSE: JNJ) today announced positive topline results from the pivotal Phase 3 GRAVITI investigational study of TREMFYA® (guselkumab) subcutaneous (SC) induction therapy in adult patients with moderately to severely active Crohn's disease.1 The study met both co-primary endpoints, achieving statistically significant and clinically meaningful outcomes for clinical remission at Week 12 as well as endoscopic response at Week 12. All remaining multiplicity-controlled secondary endpo